Company News

BlinkLab engages leading autism research centre for main study phase of US diagnostic trial May 21, 2025

BlinkLab (ASX:BB1) has announced the commencement of the main study phase of its pivotal US-based FDA 510(k) diagnostic trial for its smartphone-based autism diagnostic tool, with the engagement of a significant new clinical site.

Chimeric advances CHM CDH17 clinical trial to Dose Level 2 May 21, 2025

Chimeric Therapeutics (ASX:CHM) has announced that the CHM CDH17 clinical trial has advanced to Dose Level 2, following the observation of no safety concerns or off-target effects at Dose Level 1.

Argencia granted new US patent for surgically induced stroke May 21, 2025

Argenica managing director Dr Liz Dallimore said, “Our new divisional US patent further strengthens Argenica’s already wide-ranging protection for neuroprotective peptides."

Zelira Therapeutics announces full publication of IRB approved observational study May 21, 2025

Zelira Therapeutics (ASX:ZLD) has announced the publication of its clinical study report, which evaluated its ZLT-L-007 in 60 adults diagnosed with diabetic neuropathy.

Dimerix updates on latest IDMC review of ACTION3 Phase 3 kidney trial May 21, 2025

Dimerix (ASX:DXB) has confirmed that the Independent Data Monitoring Committee successfully concluded a sixth review of the ACTION3 phase 3 clinical trial safety data.

Adherium announces additional capital raise to progress US smartinhaler roll-out May 19, 2025

Digital health company Adherium (ASX:ADR) has received firm commitments to raise a total of $900,000 through the issuance of approximately 900,000 convertible notes.

LTR Pharma says access to Spontan expanded to more pharmacies May 19, 2025

LTR Pharma (ASX:LTP) has announced that SPONTAN is now available through TerryWhite Chemmart's national pharmacy network.

Noxopharm secures new funds from Nyrada share sale May 19, 2025

Noxopharm (ASX:NOX) has announced it has raised additional working capital by disposing of its entire shareholding in Nyrada (ASX:NYR).

Avecho says new sites commence recruitment for its pivotal Phase 3 clinical trial May 19, 2025

Avecho Biotechnology (ASX:AVE) has provided an update on its oral cannabidiol TPM-enhanced capsule development program, confirming that all three new sites for the Phase 3 clinical trial have commenced screening and recruitment.

Report highlights international confidence in Australian clinical trials May 19, 2025

Global investment in Australian clinical trials is strong, according to Bellberry's 2024 Clinical Trials Activity Report.

PolyNovo's NovoSorb BTM delivers positive first in human results in diabetes May 14, 2025

PolyNovo (ASX:PNV) has announced that Professor Toby Coates AO, the director of Beta Cell Technologies, has presented the results of the company's NovoSorb and its potential role in treating and managing Type 1 diabetes.

Amplia reports updated positive data from ACCENT trial in pancreatic cancer May 14, 2025

Amplia Therapeutics (ASX:ATX) has announced updated data from its ongoing ACCENT clinical trial of its narmafotinib in combination with chemotherapies gemcitabine and abraxane in pancreatic cancer.

Most Read

New Stories

BlinkLab engages leading autism research centre for main study phase of US diagnostic trial

Chimeric advances CHM CDH17 clinical trial to Dose Level 2

Argencia granted new US patent for surgically induced stroke

Zelira Therapeutics announces full publication of IRB approved observational study

Dimerix updates on latest IDMC review of ACTION3 Phase 3 kidney trial

Adherium announces additional capital raise to progress US smartinhaler roll-out

LTR Pharma says access to Spontan expanded to more pharmacies

Sign In